Alkem Laboratories Limited (NSE: ALKEM)
India
· Delayed Price · Currency is INR 6,309.95
+33.40 (0.53%)
Sep 6, 2024, 3:29 PM IST
Alkem Laboratories Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Net Income | - | 17,958 | 9,842 | 16,456 | 15,850 | 11,271 | Upgrade
|
| Depreciation & Amortization | - | 2,860 | 2,986 | 2,936 | 2,648 | 2,436 | Upgrade
|
| Other Amortization | - | 133.5 | 118.1 | 103.7 | 97.6 | 91.5 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | 31.8 | 123.6 | 14.3 | -388 | -12.6 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 992.2 | 1,052 | 11.2 | - | 32.7 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | -151.7 | -308.6 | 35.2 | -369.5 | 171.4 | Upgrade
|
| Stock-Based Compensation | - | 189.4 | - | - | 1.1 | 1.5 | Upgrade
|
| Provision & Write-off of Bad Debts | - | 524 | 48.8 | 27.8 | -32.1 | 101.7 | Upgrade
|
| Other Operating Activities | - | -2,539 | -303.9 | -3,025 | -1,747 | -1,770 | Upgrade
|
| Change in Accounts Receivable | - | -2,220 | -1,347 | -2,218 | -257.6 | -2,574 | Upgrade
|
| Change in Inventory | - | -734 | 4,734 | -6,731 | -4,977 | -2,817 | Upgrade
|
| Change in Accounts Payable | - | 5,253 | 145.1 | 3,345 | 2,124 | -37.4 | Upgrade
|
| Change in Other Net Operating Assets | - | -2,816 | -264.4 | 154.4 | -301.2 | -1,043 | Upgrade
|
| Operating Cash Flow | - | 19,481 | 16,825 | 11,110 | 12,649 | 5,851 | Upgrade
|
| Operating Cash Flow Growth | - | 15.78% | 51.44% | -12.17% | 116.19% | -24.96% | Upgrade
|
| Capital Expenditures | - | -2,593 | -2,329 | -3,389 | -1,949 | -3,631 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 724.8 | 32 | 109 | 104.6 | 154.5 | Upgrade
|
| Sale (Purchase) of Intangibles | - | - | - | - | 351 | - | Upgrade
|
| Investment in Securities | - | -10,612 | 1,955 | -12,051 | -9,286 | -4,454 | Upgrade
|
| Other Investing Activities | - | 2,395 | 1,471 | 979.6 | 794.3 | 516.8 | Upgrade
|
| Investing Cash Flow | - | -10,085 | 1,128 | -14,351 | -9,985 | -7,414 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 8,821 | 1,784 | 7,841 | Upgrade
|
| Long-Term Debt Issued | - | 400 | - | - | - | - | Upgrade
|
| Total Debt Issued | - | 400 | - | 8,821 | 1,784 | 7,841 | Upgrade
|
| Short-Term Debt Repaid | - | -5,209 | -12,690 | - | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -323.2 | -333.4 | -404.6 | -617.7 | -2,004 | Upgrade
|
| Total Debt Repaid | - | -5,532 | -13,023 | -404.6 | -617.7 | -2,004 | Upgrade
|
| Net Debt Issued (Repaid) | - | -5,132 | -13,023 | 8,416 | 1,167 | 5,838 | Upgrade
|
| Common Dividends Paid | - | -5,380 | -2,272 | -4,185 | -3,348 | -3,587 | Upgrade
|
| Other Financing Activities | - | -937.6 | 675.9 | -435.6 | -536.2 | -1,459 | Upgrade
|
| Financing Cash Flow | - | -11,450 | -17,608 | 3,796 | -2,718 | 791.5 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | -20.5 | 71 | 25 | 36.7 | 40.1 | Upgrade
|
| Net Cash Flow | - | -2,075 | 416.2 | 579.6 | -17.2 | -731.1 | Upgrade
|
| Free Cash Flow | - | 16,888 | 14,496 | 7,721 | 10,700 | 2,220 | Upgrade
|
| Free Cash Flow Growth | - | 16.50% | 87.74% | -27.84% | 382.00% | -11.38% | Upgrade
|
| Free Cash Flow Margin | - | 13.33% | 12.50% | 7.26% | 12.07% | 2.66% | Upgrade
|
| Free Cash Flow Per Share | - | 141.24 | 121.24 | 64.58 | 89.49 | 18.57 | Upgrade
|
| Cash Interest Paid | - | 913.1 | 904.6 | 401.3 | 536.2 | 542.6 | Upgrade
|
| Cash Income Tax Paid | - | 4,069 | 2,734 | 3,969 | 4,007 | 3,589 | Upgrade
|
| Levered Free Cash Flow | - | 31,077 | 5,554 | -6,087 | 12,350 | -6,551 | Upgrade
|
| Unlevered Free Cash Flow | - | 31,579 | 6,059 | -5,894 | 12,599 | -6,260 | Upgrade
|
| Change in Net Working Capital | - | -18,693 | 2,963 | 16,440 | -988 | 13,071 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.